ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-nectin-4 Antibody-drug Conjugate IPH4502

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Innate Pharma.

Furthest: phase 1, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Apr 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innate Pharma11 open or runningphase 1since Jan 8, 2025Jan 8, 2025Apr 2028phase 1 · NCT06781983

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2025First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06781983 · 145 enrolled · United States, France

Ahead

  1. Apr 2028Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06781983

TargetBeta

NECTIN4 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) Fc-competent monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06781983Squamous Cell Carcinoma of Head and Neck · United States, France1Active, not recruitingApr 2028145

How it is read

Names in the registry

  • “IPH4502”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.